In both the Tsc2+/- mouse model and nude mouse model for TSC tumors, the timing of initiation of mTOR inhibitor treatment of TSC-related tumors does not appear to be important, provided that tumors are actively growing at the time treatment is initiated. Here, TSC2 is linked to tuberous sclerosis.